Next, we give an answer to the values for which we have been asked the most throughout the morning. José María Rodríguez, technical analyst at Bolsamanía, analyzes Faes Farma, Soltec, Solaria, Cellnex, Nel Asa, DIA, Santander and PharmaMar.
Good morning, Don José María. First of all, thank you for your accurate analysis. My question is about Faes. After the last crashes, has your technical profile changed? Thanks a lot. F.B.
Dear reader, good afternoon. Although violent, I recognize that the latest declines in the Faes I don't dislike them. And this is so because they fit, to the penny, within what is a 'throw back' to the new support zone, before resistance, which gives it the old bullish channel through which the price has been moving from April to November . That is to say, there is still the possibility that from here it will try to restructure upward again, or at least as far as the short term is concerned. In terms of the medium and long term, it is vital that the support presented at the October lows (3,025) holds at all times. Thanks to you, greetings.
Good Morning. Thanks for all the analysis you provide, I would like if it were possible to analyze Soltec and Solaria. Do you think that both can have a run? Thank you. J.V.
Dear investor, good afternoon. Soltec it is a value at historical highs and therefore and as it cannot be otherwise very bullish. It has a long history in the stock market, which makes it difficult to do a more or less deep technical analysis. But despite this the graph is clear. We have an impeccable short-term bullish guideline that joins the successive rising lows since the beginning of November. This straight support passes at the current moment by approximately 6.75 euros. The increasing minimums and maximums follow one another and therefore it is a clear hold in the portfolio. The only "but" in this title is that it is quite illiquid, not very narrow. And this can make it difficult to enter / exit it. But the important thing is that it is clearly bullish.
As to Solaria, of which we have talked a lot in the last weeks / months, is already very close to the important resistance it has at the historical highs: 24.26 euros. This level corresponds to the maximums that it marked in November 2007. And above and as you already know, it will be placed in an absolute free rise, with the upward implications that this usually has for prices. A greeting.
Good morning, José María. If I could, I would like you to analyze Cellnex, with the most immediate support and resistance, and to know how the stock can behave in the medium / long term. Thanks a lot. Regards. J.SR.
Dear reader, good afternoon. Cellnex it is still a bullish value in medium and long term terms. Which is not an impediment for the price to be displaying a wide lateral movement. In fact, as we know there are two ways to correct in the markets: consuming time or in depth (falls). And in the case that concerns us, it seems that we are in the first of the options. On the other hand, we have an important support zone around the corner: the straight support that joins the last rising lows and that currently passes for approximately 46 euros. Today it is a stop, a halt on the road within an impeccable bottom uptrend. A greeting.
Good morning, José María. I would appreciate your comment on how you see the Norwegian action Nel Asa (NELO), a benchmark in renewable energy, and especially in relation to hydrogen. It is a sector that I understand has a great future projection and I would like to hear your expert opinion on whether it is the right time to invest in this company. Many thanks. Regards. E.CL.
Dear investor, good afternoon. Nel Asa it's a clearly bullish stock that can hit new all-time highs at any time. In the short term it is triangulating, shaping a small symmetrical triangle with bullish implications. And all this within a medium-term bullish channel through which the price continues to move since mid-2019. Price dilations aside, the upper part of the channel (by definition resistance) is currently passing around 29 NOK (crowns). Norwegian). The chart cannot be more bullish and, a priori, any correction of some importance (reaction phase) that sometimes occurs should be interpreted as an opportunity to climb into the bottom uptrend. Thank you very much, greetings.
Hello. My query is about DIA, could you analyze it with the graph included? What prospects do you think you have in the medium-long term? Thanks and regards. L.M.
Dear reader, good afternoon. DAY It is a title that we have been repeating the same over and over again. It is bearish in terms of the medium and long term and the operation, in the short, sticks to the wide lateral movement with support at 0.10 and resistance at 0.15 euros. Until the title comes out of there we won't have any clues about the next big move in trend. And meanwhile the strategy cannot be other than to open longs in the support zone of 0.10 euros and close them in the zone of 0.15 euros. And meanwhile, to wait. Thanks to you, greetings.
Hello, Mr. Rodríguez. I have shares in PharmaMar and Santander from when the ‘rally’ over the Pfizer vaccine. Santander at 2.07 euros and PharmaMar at 118 euros. Almost the second one worries me more. How do you see them a year from now? My congratulations for this section that I never miss. I.AR.
Dear investor, good afternoon. PharmaMar we analyzed it on Monday in this section and as you can imagine nothing has changed. The biotech company remains in the corrective phase. However, in terms of the medium and long term, it is still clearly bullish. That said, I acknowledge that since the mid-June bull gap closed / canceled and the September lows were pierced, the value is no longer the same. Let's say you have lost 'momentum' (cruising speed). Important supports have been drilled and therefore the corrective phase can be prolonged. In fact, a rebound towards the area of 93.60 euros would fill the last of the large bearish gaps left by the price in recent months and little else. Not to mention the flawless highs and lows declining since mid-October. All in all, the bottom trend from the 2018 lows remains clearly bullish to this day.
As to Santander, the graph is a copy of the Ibex in the sense that the two underlying assets have partially filled the weekly bearish gap in March and have since collapsed. Something that on the other hand we already commented in previous analyzes that it was normal, that it was within the normal range. Since these types of bearish gaps, so wide, rarely close on the first occasion that it presents itself. The normal thing is to fill it in on the first try and then, the next time, the probability of success is usually higher. The rise from the October lows has been of such magnitude (100%) that a correction towards the two euro area would be a simple adjustment / setback of 61.8% of the entire previous rise. The problem with this title is that in addition to the weekly bearish gap of 2.92 euros we have another important resistance in the bearish guideline, now at 3.25 euros. Thanks to you, greetings.
Still don't know about Trader Watch? TW is a service that offers continuous real-time monitoring of financial markets, looking for the best investment opportunities at all times
Note: Investment decision making must be done in a responsible manner and being aware of the risks that are assumed. Web Financial Group accepts no responsibility for the content and analysis of the practice. It is also noted that trading in the stock market involves a high risk and implies constant monitoring of the position.
. (tagsToTranslate) Office (t) technical analysis (t): (t) Santander (t) PharmaMar (t) Faes (t) Solaria (t) Cellnex (t) DIA (t) Soltec (t) Category: All (t) ) Category: Market Report (t) Category: Technical Analysis (t) Category: Pulses (t) Category: Analysis (t) Category: Market Pulse (t) Category: Sectorial: Consumer Services (t) Category: Sectorial: Retail Trade ( t) Category: Sectorial: Utilities (t) Category: Sectorial: Finance (t) mostread_ultimas (t) mostread_fundsnews (t) mostread_analisis-tecnico (t) mostread_analisis (t) mostread_mercados